Cue Biopharma stockholders approve reverse stock split with ratio 1:30 to 1:50

Cue Biopharma, Inc.

Elected Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot to the Board.
Ratified RSM US LLP as independent auditor for FY2026 with 58,982,168 votes for.
Approved non-binding advisory say-on-pay with 31,388,709 for, 4,239,819 against.
Approved reverse stock split amendment at 51,011,729 for; ratio range 1-for-30 to 1-for-50 at Board's discretion.
Prior CEO Usman Azam resigned March 26, 2026; votes for him were disregarded.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.